Accessibility Menu
Codexis logo

Codexis(NASDAQ) CDXS

Current Price$1.48
Market Cap$134.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-89%
5 Year-93%
1 Year-54%
1 Month-35%
Codexis last closing stock price
MetricPriceDate
Last closeUSD 1.482026-07-24
Codexis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-33.93%USD 2.242026-07-17
1 month-34.8%USD 2.272026-06-24
3 month-43.51%USD 2.622026-04-24
Year to date-9.2%USD 1.632025-12-31
1 year-54.32%USD 3.242025-07-24
3 year-56.98%USD 3.442023-07-25
5 year-92.94%USD 20.952021-07-23
Since inception-88.84%USD 13.262010-04-22

Codexis Financials at a Glance

Market Cap

$134.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$78.09M

Net Income (TTM)

-$31.99M

EPS (TTM)

-$0.36

P/E Ratio

-4.08

Dividend

$0.00

Beta (Volatility)

1.96 (High)

Price

$1.48

Volume

9,192.834

Open

$1.49

Previous Close

$1.48

Daily Range

$1.44 - $1.57

52-Week Range

$0.96 - $3.87

Estimated Earnings Date

Aug 12, 2026

CDXS News

Foolcom-Featured.png

Codexis Revenue Jumps 91 Percent in Q2

Motley Fool Markets TeamAug 13, 2025
GettyImages-526637899

Up Over 500% in the Last 5 Years, Can This Biotech Continue Its Hot Streak?

Patrick BafumaOct 20, 2021
120 fish bowl jump

Codexis Dodges Coronavirus Slowdown in Q2

Maxx ChatskoAug 11, 2020
534 question cards wooden box

Should Codexis Investors Prepare for Slower Growth?

Maxx ChatskoMay 22, 2020
220 is a buy

Near a 2-Year Low, Is Codexis Stock a Buy?

Maxx ChatskoApr 15, 2020
563 shocked phone

Codexis Expects Its Most Important Source of Revenue to Decline in 2020

Maxx ChatskoFeb 29, 2020
stock sliding chalkboard

Here's Why Codexis Fell as Much as 20.0% Today

Maxx ChatskoFeb 28, 2020
410 binoculars kid

What to Watch When Codexis Reports 2019 Operating Results

Maxx ChatskoFeb 26, 2020
Page 1

CDXS: Motley Fool Moneyball Superscore

52

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Codexis

Codexis makes specialized proteins that help drug companies manufacture medicine. These proteins speed up chemical reactions to make drug production cleaner and cheaper. The company helps create treatments for complex diseases more efficiently.

The Protein Menu

  • Pharma Biocatalysis: Engineered enzymes that improve how pharmaceutical companies manufacture small-molecule drugs.
  • ECO Synthesis Platform: Enzymatic tools designed for the large-scale production of RNA-based therapeutics.
  • Molecular Biology Enzymes: High-performance proteins used in diagnostic testing and genomic research.
  • Biocatalyst Panels: Kits and screening services that allow customers to test chemistry for drug development.

Strategic Steps

  • Entered into partnerships with three large-scale contract manufacturers in 2025 to scale up production of RNAi drug substances.
  • Recognized $6.3 million in revenue during Q1 2026 from a licensing agreement with Merck signed in late 2025.
  • Completed the build-out of the ECO Synthesis Innovation Lab at the end of 2024 to provide specialized manufacturing services.
  • Secured a $40 million term loan from Innovatus to fund operations and technology development through 2029.

How Codexis Stands Out

The company uses its proprietary CodeEvolver platform to engineer enzymes that survive harsh industrial environments where natural proteins fail. This technology allows pharmaceutical manufacturers to reduce energy usage and waste while increasing the purity of their final products.

By the Numbers

  • Total revenue rose to $15.2 million in Q1 2026, a 102.1% increase compared to Q1 2025.
  • Net loss narrowed to $8.7 million in Q1 2026, an improvement from the $20.7 million loss reported in Q1 2025.
  • Product gross margin reached 71% in the first quarter of 2026, up from 55% in the same period last year.
  • Total cash and short-term investments stood at $65.1 million as of March 31, 2026.

The Verdict

Codexis is shifting its focus from general protein engineering toward specialized manufacturing platforms for high-growth RNA therapeutics. This transition, combined with recent cost-cutting and licensing deals, aims to stabilize its financial position.

AI Generated • May 19, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

146

CEO

Alison Moore, PhD

Website

www.codexis.com

Headquarters

Redwood City, CA 94063, US

CDXS Financials

Key Financial Metrics (TTM)

Gross Margin

83.94%

Operating Margin

-33.15%

Net Income Margin

-40.96%

Return on Equity

-68.09%

Return on Capital

-30.98%

Return on Assets

-24.73%

Earnings Yield

-24.51%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$134.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

90.90M

Volume

9.19K

Avg. Volume

1.09M

Financials (TTM)

Gross Profit

$65.55M

Operating Income

-$25.89M

EBITDA

-$22.06M

Operating Cash Flow

-$18.73M

Capital Expenditure

-$3.39M

Free Cash Flow

-$22.12M

Cash & ST Invst.

$65.57M

Total Debt

$72.90M

Codexis Performance Analysis

Codexis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 138,590,00032.3%
20232023-12-31USD 70,143,000-49.4%
20242024-12-31USD 59,345,000-15.4%
20252025-12-31USD 70,387,00018.6%
Codexis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30103.2%
Q32025-09-30-43.9%
Q42025-12-31352.4%
Q12026-03-31-60.8%
Codexis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.5156.0%
20232023-12-31USD -1.12117.7%
20242024-12-31USD -0.89-20.5%
20252025-12-31USD -0.50-43.3%
Codexis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3036.0%
Q32025-09-30-37.5%
Q42025-12-31150.0%
Q12026-03-31-187.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$15.25M

+102.1%

Gross Profit

$11.94M

+148.1%

Gross Margin

78.28%

N/A

Market Cap

$134.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$921.42K

N/A

Employees

146

N/A

Net Income

-$8.70M

+57.9%

EBITDA

-$6.45M

+63.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$65.57M

+9.7%

Total Debt

$72.90M

+22.5%

Accounts Receivable

$8.03M

-30.7%

Inventory

$2.00M

+12.3%

Long Term Debt

$69.60M

+23.0%

Short Term Debt

$3.30M

+13.4%

Return on Assets

-24.73%

N/A

Return on Invested Capital

-22.61%

N/A

Free Cash Flow

-$13.33M

+11.5%

Operating Cash Flow

-$13.15M

+4.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMDXInsight Molecular Diagnostics Inc.
$4.74-4.44%
IPHAInnate Pharma S.A.
$1.78+1.14%
IVVDInvivyd, Inc.
$0.61+0.36%
RANIRani Therapeutics Holdings, Inc.
$0.85-4.39%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
NOKNokia
$9.10-0.06%
STAKStak
$9.27+6.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$31.27-0.14%

Questions About CDXS

What is the current price of Codexis?

Codexis is trading at $1.48 per share.

What is the 52-week range for Codexis?

Over the past 52 weeks, Codexis has traded between $0.96 and $3.87.

How much debt does Codexis have?

As of the most recent reporting period, Codexis reported total debt of $72.90M.

How much cash does Codexis have on hand?

Codexis reported $37.00M in cash and cash equivalents in its most recent financial results.

What is Codexis’s dividend yield?

Codexis does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services